
Lecanemab gets EU approval in early Alzheimer’s
The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU). The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU. Lecanemab is indicated for the treatment of adult patients… Read More














